Vitamin D and neurocognitive function

Clinical Interventions in Aging

Volumn 9, Issue , 2014, Pages 559-568

  Schlögl, Mathias ^a   Holick, Michael F ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

25(OH)D level; Alzheimer's disease; Cognition; Mild cognitive impairment; Vascular dementia; Vitamin D

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; VITAMIN D; VITAMIN D RECEPTOR;

AGING; ALZHEIMER DISEASE; COGNITION; COGNITIVE DEFECT; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; GERIATRIC NUTRITION; HIGH RISK POPULATION; HUMAN; MALNUTRITION; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NEUROPATHOLOGY; NEUROPROTECTION; REVIEW; RISK FACTOR; RISK REDUCTION; VITAMIN D DEFICIENCY; VITAMIN INTAKE; VITAMIN METABOLISM; AGED; COMPLICATION; METABOLISM; PHYSIOLOGY;

AGED; AGING; ALZHEIMER DISEASE; COGNITION; HUMANS; MALNUTRITION; MILD COGNITIVE IMPAIRMENT; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84897511718     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S51785     Document Type: Review

References (147)

1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3): 266-281.
2. Dobs AS, Levine MA, Margolis S. Effects of pravastatin, a new HMG-CoA reductase inhibitor, on vitamin D synthesis in man. Metabolism. 1991;40(5):524-528.
3. Godar DE, Pope SJ, Grant WB, Holick MF. Solar UV doses of adult Americans and vitamin D(3) production. Dermatoendocrinol. 2011;3(4):243-250.
4. Holick MF. Optimal vitamin D status for the prevention and treatment of osteoporosis. Drugs Aging. 2007;24(12):1017-1029.
5. Holick MF. Evolution and function of vitamin D. Recent Results Cancer Res. 2003;164:3-28.
6. Lehmann B, Tiebel O, Meurer M. Expression of vitamin D3 25-hydroxylase (CYP27) mRNA after induction by vitamin D3 or UVB radiation in keratinocytes of human skin equivalents-a preliminary study. Arch Dermatol Res. 1999;291(9):507-510.
7. Bikle DD, Halloran BP, Riviere JE. Production of 1,25 dihydroxyvitamin D3 by perfused pig skin. J Invest Dermatol. 1994;102(5):796-798.
8. Seifert M, Tilgen W, Reichrath J. Expression of 25-hydroxyvitamin D-1alpha-hydroxylase (1alphaOHase, CYP27B1) splice variants in HaCaT keratinocytes and other skin cells: modulation by culture conditions and UV-B treatment in vitro. Anticancer Res. 2009;29(9): 3659-3667.
9. Fu GK, Lin D, Zhang MY, etal. Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol. 1997;11(13):1961-1970.
10. Lehmann B, Genehr T, Knuschke P, Pietzsch J, Meurer M. UVB-induced conversion of 7-dehydrocholesterol to 1alpha, 25-dihydroxyvitamin D3 in an in vitro human skin equivalent model. J Invest Dermatol. 2001;117(5):1179-1185.
11. Mangelsdorf DJ, Thummel C, Beato M, etal. The nuclear receptor superfamily: the second decade. Cell. 1995;83(6):835-839.
12. Sutherland MK, Somerville MJ, Yoong LK, Bergeron C, Haussler MR, McLachlan DR. Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28k mRNA levels. Brain Res Mol Brain Res. 1992;13(3):239-250.
13. Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat. 2005;29(1):21-30.
14. Dhikav V, Anand K. Potential predictors of hippocampal atrophy in Alzheimer's disease. Drugs Aging. 2011;28(1):1-11.
15. Mu Y, Gage FH. Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol Neurodegener. 2011;6:85.
16. Fotuhi M, Do D, Jack C. Modifiable factors that alter the size of the hippocampus with ageing. Nat Rev Neurol. 2012;8(4):189-202.
17. Calabresi P, Castrioto A, Di Filippo M, Picconi B. New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. Lancet Neurol. 2013;12(8):811-821.
18. Nimitphong H, Holick MF. Vitamin D, neurocognitive functioning and immunocompetence. Curr Opin Clin Nutr Metab Care. 2011; 14(1):7-14.
19. Beydoun MA, Ding EL, Beydoun HA, Tanaka T, Ferrucci L, Zonderman AB. Vitamin D receptor and megalin gene polymorphisms and their associations with longitudinal cognitive change in US adults. Am J Clin Nutr. 2012;95(1):163-178.
20. Kuningas M, Mooijaart SP, Jolles J, Slagboom PE, Westendorp RG, van Heemst D. VDR gene variants associate with cognitive function and depressive symptoms in old age. Neurobiol Aging. 2009;30(3): 466-473.
21. Luedecking-Zimmer E, DeKosky ST, Nebes R, Kamboh MI. Association of the 3′ UTR transcription factor LBP-1c/CP2/LSF polymorphism with late-onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 2003;117B(1):114-117.
22. Gezen-Ak D, Dursun E, Ertan T, etal. Association between vitamin D receptor gene polymorphism and Alzheimer's disease. Tohoku J Exp Med. 2007;212(3):275-282.
23. Lehmann DJ, Refsum H, Warden DR, Medway C, Wilcock GK, Smith AD. The vitamin D receptor gene is associated with Alzheimer's disease. Neurosci Lett. 2011;504(2):79-82.
24. Gezen-Ak D, Dursun E, Bilgiç B, etal. Vitamin D receptor gene haplotype is associated with late-onset Alzheimer's disease. Tohoku J Exp Med. 2012;228(3):189-196.
25. Kim JS, Kim YI, Song C, etal. Association of vitamin D receptor gene polymorphism and Parkinson's disease in Koreans. J Korean Med Sci. 2005;20(3):495-498.
26. Butler MW, Burt A, Edwards TL, etal. Vitamin D receptor gene as a candidate gene for Parkinson disease. Ann Hum Genet. 2011;75(2): 201-210.
27. Han X, Xue L, Li Y, Chen B, Xie A. Vitamin D receptor gene polymorphism and its association with Parkinson's disease in Chinese Han population. Neurosci Lett. 2012;525(1):29-33.
28. Lv Z, Tang B, Sun Q, Yan X, Guo J. Association study between vitamin d receptor gene polymorphisms and patients with Parkinson disease in Chinese Han population. Int J Neurosci. 2013;123(1):60-64.
29. Török R, Török N, Szalardy L, etal. Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians. Neurosci Lett. 2013;551:70-74.
30. Krizova L, Kollar B, Jezova D, Turcani P. Genetic aspects of vitamin D receptor and metabolism in relation to the risk of multiple sclerosis. Gen Physiol Biophys. Epub September 26, 2013.
31. MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest. 1985;76(4):1536-1538.
32. Harris SS, Dawson-Hughes B. Plasma vitamin D and 25OHD responses of young and old men to supplementation with vitamin D3. J Am Coll Nutr. 2002;21(4):357-362.
33. Gallagher JC, Rapuri P, Smith L. Falls are associated with decreased renal function and insufficient calcitriol production by the kidney. J Steroid Biochem Mol Biol. 2007;103(3-5):610-613.
34. Armbrecht HJ, Zenser TV, Davis BB. Effect of age on the conversion of 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3 by kidney of rat. J Clin Invest. 1980;66(5):1118-1123.
35. Need AG, Morris HA, Horowitz M, Nordin C. Effects of skin thickness, age, body fat, and sunlight on serum 25-hydroxyvitamin D. Am J Clin Nutr. 1993;58(6):882-885.
36. Holick MF, Matsuoka LY, Wortsman J. Age, vitamin D, and solar ultraviolet. Lancet. 1989;2(8671):1104-1105.
37. Gau JT. Prevalence of vitamin D deficiency/insufficiency practice patterns in nursing homes. J Am Med Dir Assoc. 2010;11(4):296.
38. Morley JE. Vitamin d redux. J Am Med Dir Assoc. 2009;10(9): 591-592.
39. Braddy KK, Imam SN, Palla KR, Lee TA. Vitamin d deficiency/insufficiency practice patterns in a veterans health administration long-term care population: a retrospective analysis. J Am Med Dir Assoc. 2009;10(9):653-657.
40. Perry HM, Horowitz M, Morley JE, etal. Longitudinal changes in serum 25-hydroxyvitamin D in older people. Metabolism. 1999;48(8): 1028-1032.
41. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381(9868):752-762.
42. Welge-Lüssen A. Ageing, neurodegeneration, and olfactory and gustatory loss. B-ENT. 2009;5 Suppl 13:129-132.
43. Methven L, Allen VJ, Withers CA, Gosney MA. Ageing and taste. Proc Nutr Soc. 2012;71(4):556-565.
44. Guiglia R, Musciotto A, Compilato D, etal. Aging and oral health: effects in hard and soft tissues. Curr Pharm Des. 2010;16(6):619-630.
45. Zadak Z, Hyspler R, Ticha A, Vlcek J. Polypharmacy and malnutrition. Curr Opin Clin Nutr Metab Care. 2013;16(1):50-55.
46. Tamura BK, Bell CL, Masaki KH, Amella EJ. Factors associated with weight loss, low BMI, and malnutrition among nursing home patients: a systematic review of the literature. J Am Med Dir Assoc. 2013;14(9): 649-655.
47. van Bokhorst-de van der Schueren MA, Lonterman-Monasch S, de Vries OJ, Danner SA, Kramer MH, Muller M. Prevalence and determinants for malnutrition in geriatric outpatients. Clin Nutr. 2013;32(6):1007-1011.
48. Roqué M, Salvà A, Vellas B. Malnutrition in community-dwelling adults with dementia (NutriAlz Trial). J Nutr Health Aging. 2013;17(4):295-299.
49. Ikeda M, Brown J, Holland AJ, Fukuhara R, Hodges JR. Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;73(4): 371-376.
50. Manthorpe J, Watson R. Poorly served? Eating and dementia. J Adv Nurs. 2003;41(2):162-169.
51. Greenwood CE, Tam C, Chan M, Young KW, Binns MA, van Reekum R. Behavioral disturbances, not cognitive deterioration, are associated with altered food selection in seniors with Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2005;60(4): 499-505.
52. Allen VJ, Methven L, Gosney MA. Use of nutritional complete supplements in older adults with dementia: Systematic review and meta-analysis of clinical outcomes. Clin Nutr. Epub Mar 28, 2013.
53. Holick MF, Binkley NC, Bischoff-Ferrari HA, etal; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930.
54. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Ross AC, Taylor CL, Yaktine AL, Del Valle HB, editors. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Press (US); 2011.
55. Hagenau T, Vest R, Gissel TN, etal. Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. Osteoporos Int. 2009;20(1):133-140.
56. Wahl DA, Cooper C, Ebeling PR, etal. A global representation of vitamin D status in healthy populations. Arch Osteoporos. 2012; 7(1-2):155-172.
57. Hossein-Nezhad A, Holick MF. Vitamin d for health: a global perspective. Mayo Clin Proc. 2013;88(7):720-755.
58. van der Wielen RP, Löwik MR, van den Berg H, etal. Serum vitamin D concentrations among elderly people in Europe. Lancet. 1995;346(8969):207-210.
59. Ganji V, Zhang X, Tangpricha V. Serum 25-hydroxyvitamin D concentrations and prevalence estimates of hypovitaminosis D in the US population based on assay-adjusted data. J Nutr. 2012;142(3): 498-507.
60. Valtueña J, Gracia-Marco L, Huybrechts I, etal; Helena Study Group. Cardiorespiratory fitness in males, and upper limbs muscular strength in females, are positively related with 25-hydroxyvitamin D plasma concentrations in European adolescents: the HELENA study. QJM. 2013;106(9):809-821.
61. Anderson JL, May HT, Horne BD, etal; Intermountain Heart Collaborative (IHC) Study Group. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106(7):963-968.
62. Kienreich K, Tomaschitz A, Verheyen N, etal. Vitamin D and cardiovascular disease. Nutrients. 2013;5(8):3005-3021.
63. Chabas JF, Alluin O, Rao G, etal. Vitamin D2 potentiates axon regeneration. J Neurotrauma. 2008;25(10):1247-1256.
64. Brown J, Bianco JI, McGrath JJ, Eyles DW. 1,25-dihydroxyvitamin D3induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett. 2003;343(2):139-143.
65. Marini F, Bartoccini E, Cascianelli G, etal. Effect of 1alpha,25-dihydroxyvitamin D3in embryonic hippocampal cells. Hippocampus. 2010;20(6):696-705.
66. Brewer LD, Thibault V, Chen KC, Langub MC, Landfield PW, Porter NM. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci. 2001;21(1):98-108.
67. Ibi M, Sawada H, Nakanishi M, etal. Protective effects of 1 alpha,25-(OH)(2)D(3) against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology. 2001;40(6):761-771.
68. Kröncke KD, Klotz LO, Suschek CV, Sies H. Comparing nitrosative versus oxidative stress toward zinc finger-dependent transcription. Unique role for NO. J Biol Chem. 2002;277(15):13294-13301.
69. Garcion E, Sindji L, Montero-Menei C, Andre C, Brachet P, Darcy F. Expression of inducible nitric oxide synthase during rat brain inflammation: regulation by 1,25-dihydroxyvitamin D3. Glia. 1998;22(3):282-294.
70. Chen KB, Lin AM, Chiu TH. Systemic vitamin D3 attenuated oxidative injuries in the locus coeruleus of rat brain. Ann N Y Acad Sci. 2003;993:313-324; discussion 345-349.
71. Lin AM, Fan SF, Yang DM, Hsu LL, Yang CH. Zinc-induced apoptosis in substantia nigra of rat brain: neuroprotection by vitamin D3. Free Radic Biol Med. 2003;34(11):1416-1425.
72. Wion D, MacGrogan D, Neveu I, Jehan F, Houlgatte R, Brachet P. 1,25-Dihydroxyvitamin D3 is a potent inducer of nerve growth factor synthesis. J Neurosci Res. 1991;28(1):110-114.
73. Neveu I, Naveilhan P, Baudet C, Brachet P, Metsis M. 1,25-dihydroxyvitamin D3 regulates NT-3, NT-4 but not BDNF mRNA in astrocytes. Neuroreport. 1994;6(1):124-126.
74. Neveu I, Naveilhan P, Jehan F, etal. 1,25-dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. Brain Res Mol Brain Res. 1994;24(1-4):70-76.
75. Musiol IM, Feldman D. 1,25-dihydroxyvitamin D3induction of nerve growth factor in L929mouse fibroblasts: effect of vitamin D receptor regulation and potency of vitamin D3 analogs. Endocrinology. 1997;138(1):12-18.
76. Veenstra TD, Fahnestock M, Kumar R. An AP-1site in the nerve growth factor promoter is essential for 1,25-dihydroxyvitamin D3-mediated nerve growth factor expression in osteoblasts. Biochemistry. 1998;37(17):5988-5994.
77. Naveilhan P, Neveu I, Wion D, Brachet P. 1,25-Dihydroxyvitamin D3, an inducer of glial cell line-derived neurotrophic factor. Neuroreport. 1996;7(13):2171-2175.
78. Masoumi A, Goldenson B, Ghirmai S, etal. 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J Alzheimers Dis. 2009;17(3):703-717.
79. Mizwicki MT, Liu G, Fiala M, etal. 1α,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's disease patients. J Alzheimers Dis. 2013;34(1):155-170.
80. Pludowski P, Holick MF, Pilz S, etal. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmun Rev. 2013;12(10):976-989.
81. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens. 2009;27(10):1948-1954.
82. Pilz S, Tomaschitz A, März W, etal. Vitamin D, cardiovascular disease and mortality. Clin Endocrinol (Oxf). 2011;75(5):575-584.
83. Muscogiuri G, Sorice GP, Ajjan R, etal. Can vitamin D deficiency cause diabetes and cardiovascular diseases? Present evidence and future perspectives. Nutr Metab Cardiovasc Dis. 2012;22(2):81-87.
84. Wang L, Song Y, Manson JE, etal. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes. 2012;5(6):819-829.
85. Brøndum-Jacobsen P, Nordestgaard BG, Schnohr P, Benn M. 25-hydroxyvitamin D and symptomatic ischemic stroke: an original study and meta-analysis. Ann Neurol. 2013;73(1):38-47.
86. Gunta SS, Thadhani RI, Mak RH. The effect of vitamin D status on risk factors for cardiovascular disease. Nat Rev Nephrol. 2013;9(6):337-347.
87. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110(2):229-238.
88. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem. 2003;88(2):327-331.
89. 2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int. 2008;74(2): 170-179.
90. Forman JP, Williams JS, Fisher ND. Plasma 25-hydroxyvitamin D and regulation of the renin-angiotensin system in humans. Hypertension. 2010;55(5):1283-1288.
91. Sanna B, Brandt EB, Kaiser RA, etal. Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo. Proc Natl Acad Sci U S A. 2006;103(19):7327-7332.
92. Bodyak N, Ayus JC, Achinger S, etal. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A. 2007;104(43): 16810-16815.
93. Chen S, Law CS, Grigsby CL, etal. Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation. 2011;124(17):1838-1847.
94. Tarcin O, Yavuz DG, Ozben B, etal. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab. 2009;94(10):4023-4030.
95. Caprio M, Mammi C, Rosano GM. Vitamin D: a novel player in endothelial function and dysfunction. Arch Med Sci. 2012;8(1): 4-5.
96. Sypniewska G, Pollak J, Strozecki P, etal. 25-Hydroxyvitamin D, biomarkers of endothelial dysfunction and subclinical organ damage in adults with hypertension. Am J Hypertens. Epub September 16, 2013.
97. Aihara K, Azuma H, Akaike M, etal. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem. 2004;279(34):35798-35802.
98. Watson KE, Abrolat ML, Malone LL, etal. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997;96(6):1755-1760.
99. de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS. 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol. 2009;20(8):1805-1812.
100. Bos D, Vernooij MW, Elias-Smale SE, etal. Atherosclerotic calcification relates to cognitive function and to brain changes on magnetic resonance imaging. Alzheimers Dement. 2012;8(Suppl 5): S104-S111.
101. Yarchoan M, Xie SX, Kling MA, etal. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain. 2012;135(Pt 12):3749-3756.
102. Roher AE, Tyas SL, Maarouf CL, etal. Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia. Alzheimers Dement. 2011;7(4):436-444.
103. Vidal JS, Sigurdsson S, Jonsdottir MK, etal. Coronary artery calcium, brain function and structure: the AGES-Reykjavik Study. Stroke. 2010;41(5):891-897.
104. Knopman D, Boland LL, Mosley T, etal; Atherosclerosis Risk in Communities (ARIC) Study Investigators. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001;56(1):42-48.
105. Goldstein FC, Levey AI, Steenland NK. High blood pressure and cognitive decline in mild cognitive impairment. J Am Geriatr Soc. 2013;61(1):67-73.
106. Kivipelto M, Helkala EL, Hänninen T, etal. Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology. 2001;56(12):1683-1689.
107. Reitz C, Tang MX, Manly J, Mayeux R, Luchsinger JA. Hypertension and the risk of mild cognitive impairment. Arch Neurol. 2007;64(12):1734-1740.
108. Launer LJ, Ross GW, Petrovitch H, etal. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21(1):49-55.
109. Yamada M, Mimori Y, Kasagi F, Miyachi T, Ohshita T, Sasaki H. Incidence and risks of dementia in Japanese women: Radiation Effects Research Foundation Adult Health Study. J Neurol Sci. 2009;283(1-2):57-61.
110. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4(8):487-499.
111. Gorelick PB, Scuteri A, Black SE, etal; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42(9):2672-2713.
112. Petersen RC. Clinical Practice. Mild cognitive impairment. N Engl J Med. 2011;364(23):2227-2234.
113. Ganguli M, Snitz BE, Saxton JA, etal. Outcomes of mild cognitive impairment by definition: a population study. Arch Neurol. 2011;68(6):761-767.
114. Annweiler C, Schott AM, Berrut G, etal. Vitamin D and ageing: neurological issues. Neuropsychobiology. 2010;62(3):139-150.
115. Annweiler C, Allali G, Allain P, etal. Vitamin D and cognitive performance in adults: a systematic review. Eur J Neurol. 2009;16(10): 1083-1089.
116. Grant WB. Does vitamin D reduce the risk of dementia? J Alzheimers Dis. 2009;17(1):151-159.
117. Etgen T, Sander D, Bickel H, Sander K, Förstl H. Vitamin D deficiency, cognitive impairment and dementia: a systematic review and meta-analysis. Dement Geriatr Cogn Disord. 2012;33(5):297-305.
118. Llewellyn DJ, Langa KM, Lang IA. Serum 25-hydroxyvitamin D concentration and cognitive impairment. J Geriatr Psychiatry Neurol. 2009;22(3):188-195.
119. Balion C, Griffith LE, Strifler L, etal. Vitamin D, cognition, and dementia: a systematic review and meta-analysis. Neurology. 2012;79(13):1397-1405.
120. Defina PA, Moser RS, Glenn M, Lichtenstein JD, Fellus J. Alzheimer's disease clinical and research update for health care practitioners. J Aging Res. 2013;2013:207178.
121. Ferri CP, Prince M, Brayne C, etal; Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366(9503):2112-2117.
122. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology. 1992;42(3 Pt 1):473-480.
123. Román GC, Tatemichi TK, Erkinjuntti T, etal. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43(2):250-260.
124. Hachinski V. Vascular dementia: a radical redefinition. Dementia. 1994;5(3-4):130-132.
125. Plassman BL, Langa KM, Fisher GG, etal. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1-2):125-132.
126. Langbaum JB, Fleisher AS, Chen K, etal. Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol. 2013;9(7):371-381.
127. Wiesmann M, Kiliaan AJ, Claassen JA. Vascular aspects of cognitive impairment and dementia. J Cereb Blood Flow Metab. Epub September 11, 2013.
128. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol. 2010;120(3):287-296.
129. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet. 2001;357(9251):169-175.
130. White L, Small BJ, Petrovitch H, etal. Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study. J Geriatr Psychiatry Neurol. 2005;18(4): 224-227.
131. Sonnen JA, Larson EB, Crane PK, etal. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol. 2007;62(4):406-413.
132. Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis. 2009;18(3):691-701.
133. Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet. 1999;354(9182):919-920.
134. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277(10):813-817.
135. Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology. 2004;62(7):1148-1155.
136. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197-2204.
137. Zekry D, Duyckaerts C, Belmin J, Geoffre C, Moulias R, Hauw JJ. Alzheimer's disease and brain infarcts in the elderly. Agreement with neuropathology. J Neurol. 2002;249(11):1529-1534.
138. Buell JS, Dawson-Hughes B, Scott TM, etal. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology. 2010;74(1):18-26.
139. Annweiler C, Fantino B, Le Gall D, Schott AM, Berrut G, Beauchet O. Severe vitamin D deficiency is associated with advanced-stage dementia in geriatric inpatients. J Am Geriatr Soc. 2011;59(1):169-171.
140. Annweiler C, Rolland Y, Schott AM, etal. Higher vitamin D dietary intake is associated with lower risk of alzheimer's disease: a 7-year follow-up. J Gerontol A Biol Sci Med Sci. 2012;67(11):1205-1211.
141. Annweiler C, Llewellyn DJ, Beauchet O. Low serum vitamin D concentrations in Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2013;33(3):659-674.
142. Barnard K, Colón-Emeric C. Extraskeletal effects of vitamin D in older adults: cardiovascular disease, mortality, mood, and cognition. Am J Geriatr Pharmacother. 2010;8(1):4-33.
143. Annweiler C, Montero-Odasso M, Llewellyn DJ, Richard-Devantoy S, Duque G, Beauchet O. Meta-analysis of memory and executive dysfunctions in relation to vitamin D. J Alzheimers Dis. 2013;37(1): 147-171.
144. van der Schaft J, Koek HL, Dijkstra E, Verhaar HJ, van der Schouw YT, Emmelot-Vonk MH. The association between vitamin D and cognition: a systematic review. Ageing Res Rev. Epub May 29, 2013.
145. Llewellyn DJ, Lang IA, Langa KM, etal. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med. 2010;170(13): 1135-1141.
146. Slinin Y, Paudel ML, Taylor BC, etal; Osteoporotic Fractures in Men (MrOS) Study Research Group. 25-Hydroxyvitamin D levels and cognitive performance and decline in elderly men. Neurology. 2010;74(1):33-41.
147. Slinin Y, Paudel M, Taylor BC, etal; Study of Osteoporotic Fractures Research Group. Association between serum 25(OH) vitamin D and the risk of cognitive decline in older women. J Gerontol A Biol Sci Med Sci. 2012;67(10):1092-1098.